Bio-Techne
614 McKinley Place N.E.
Minneapolis
Minnesota
55413
United States
Website: http://www.bio-techne.com/
405 articles about Bio-Techne
-
Bio-Techne Announces ExoTRU Kidney Transplant Rejection Assay Data Publication
3/8/2021
Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU™ (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA assay.
-
Bio-Techne To Present At The Barclays Global Healthcare Conference - Mar 02, 2021
3/2/2021
Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 9:10 a.m. EST.
-
Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana
3/1/2021
Bio-Techne Corporation announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate test for men.
-
Bio-Techne Announces ISO 14001:2015 Certification for the EMEA region of Bio-Techne.
2/25/2021
Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its sites in Abingdon, Langley, Rennes and Wiesbaden received ISO 14001:2015 certification for Environmental Management Systems.
-
Bio-Techne and Luminary Therapeutics sign license agreement for use of Bio-Techne's TcBuster™ for the development of Luminary's CAR-T cell therapies
2/23/2021
Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster ™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing.
-
Bio-Techne To Present At Citi's 2021 Healthcare Services, Medtech, Tools & HCIT Virtual Conference
2/16/2021
Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at Citi's 2021 Healthcare Services, Medtech, Tools & HCIT Virtual Conference on Thursday, February 25, 2021 at 9:50 a.m. EST.
-
Bio-Techne Announces Paper Publication In Annals Of Oncology
2/11/2021
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges (Yu, W et al.) , in the highly rated peer-reviewed journal, Annals of Oncology ( link ).
-
Bio-Techne Announces Expanded Simple Plex Immunoassay Cartridge Portfolio
2/3/2021
Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple Plex TM immunoassay cartridge portfolio to include nine new cartridge formats.
-
Bio-Techne Releases Second Quarter Fiscal 2021 Results
2/2/2021
Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020 . Second Quarter FY2021 Snapshot Second quarter organic revenue increased by 19% (21% reported) to $224.3 million and 15% (16% reported) in the first half of fiscal 2021 to $428.5 million .
-
Bio-Techne Declares Dividend - Feb 02, 2021
2/2/2021
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2020.
-
Bio-Techne Announces Strategic Investment In Eminence
1/28/2021
Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced an initial minority strategic equity investment in Changzhou Eminence Biotechnology Co., Ltd. ("Eminence").
-
Bio-Techne To Host Conference Call On February 2, 2021 To Announce Second Quarter 2021 Financial Results
1/14/2021
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021 , at 8:00 a.m. CST to review second quarter 2021 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 2, 2
-
ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing
1/6/2021
ScaleReady’s mission is to make the business of cell and gene therapy practical and viable by providing the most simple, scalable and versatile manufacturing platform in the industry
-
Bio-Techne To Present At The 39th Annual J.P. Morgan Healthcare Conference
12/21/2020
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:00 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investo
-
Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development
12/2/2020
Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment. Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and
-
Bio-Techne To Present At The Stephens Annual Investment Conference 2020
11/11/2020
- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Stephens Annual Investment Conference 2020 on Tuesday, November 17, 2020 at 3:00 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Rela
-
Bio-Techne Releases First Quarter Fiscal 2021 Results
11/5/2020
Bio-Techne Corporation reported its financial results for the first quarter ended September 30, 2020.
-
Bio-Techne Declares Dividend - Nov 05, 2020
11/5/2020
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2020.
-
Bio-Techne To Present At The 29th Annual Credit Suisse Virtual Healthcare Conference
11/2/2020
Bio-Techne Corporation announced that Jim Hippel, Chief Financial Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, 2020 at 4:15 p.m. EST.
-
CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex Quantitative Antibody Test Kits
10/26/2020
-The quantitative test kits detect the level of COVID-19 antibodies that correlate to virus neutralization -Kantaro test achieves 97.8% sensitivity and 99.6% specificity for the presence of COVID-19 antibodies -Because no proprietary equipment is required, the Kantaro kits are scalable across global testing laboratories